Trethera Corp. received a $2.7M NIH grant to study combining TRE-515 with KRAS inhibitors for lung cancer. Learn how this ...
The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. | The emergence of ...
The RAMP 203 trial in advanced KRAS G12C–mutated non-small cell lung cancer has been discontinued due to increased ...
Among survivors of non-small cell lung cancer, nearly 8% developed non-lung secondary cancers over about 6 years, and this risk may be driven by genetic factors.
The EVEREST-2 study reported the first complete response to CAR-T cell therapy in a non-small cell lung cancer patient.
Verastem, Inc. shifts focus to VS-7375 for KRAS G12D tumors after ending RAMP-203. Click to learn about VSTM's key catalysts ...
The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...
Top articles in non–small cell lung cancer (NSCLC) include FDA approvals, improved outcomes due to certain treatments, and ...
The National Institute for Health and Care Excellence (NICE) has recommended amivantamab (Rybrevant) plus lazertinib ...
Zacks Investment Research on MSN
J&J wins FDA nod for subcutaneous version of NSCLC drug Rybrevant (revised)
Johnson & Johnson JNJ announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its EGFR/MET ...
Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for reflexive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback